New heart catheter aims to tame Life-Threatening rhythm disorder

NCT ID NCT07585968

Not yet recruiting Disease control Sponsor: Medtronic Cardiac Ablation Solutions Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 2 times

Summary

This study tests a new device (Sphere-9 catheter and Affera system) to treat ventricular tachycardia, a fast, dangerous heart rhythm, in 260 adults who have had a heart attack. Participants must have had repeated episodes despite medication or a defibrillator. The goal is to see if the procedure safely stops these episodes without needing stronger drugs for at least 6 months.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for VENTRICULAR TACHYCARDIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Arrhythmias, Cardiac cardiovascular disorder heart disorder myocardial ischemia Pathologic Processes ventricular tachycardia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

VENTRICULAR TACHYCARDIA

Contacts and locations

Locations

Texas Cardiac Arrhythmia Research Foundation

Austin, Texas, 78705-1852, United States
The Ohio State University Wexner Medical Center

Columbus, Ohio, 43210-1240, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.